KYNTRA BIO, INC.
Public company- Headquarters
- SAN FRANCISCO, California
- Ticker
- KYNB
- CIK
- 0000921299
WARN notices since 2024
Workers affected since 2024
Executive changes, last 12 months
Last event
Workers affected over time
Cumulative workers in WARN notices since 2024
Not enough notices to chart yet.
Leadership
| Role and person | Since | Change |
|---|---|---|
| Class III directorAndrew E. Singer, MBA | Oct 1, 2026 | Appointed |
| directorMaykin Ho, Ph.D. | Oct 1, 2026 | Departed |
Related companies
Same industry and state, with recent events.
- ACADIA PHARMACEUTICALS INC
Executive Vice President, Head of Research and Development departs: Elizabeth H.Z. Thompson, Ph.D.
- BIOMARIN PHARMACEUTICAL INC
WARN notice: Novato, CA
- CORCEPT THERAPEUTICS INC
President of Corcept Endocrinology departs: Sean Maduck
- Oruka Therapeutics, Inc.
Chief Commercial Officer appointed: Todd Edwards
- Executive appointment
Class III director appointed: Andrew E. Singer, MBA
Andrew E. Singer, MBA was named Class III director of KYNTRA BIO, INC., effective October 1, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Oct 1, 2026Role: Class III director
- Executive departure
director departs: Maykin Ho, Ph.D.
Maykin Ho, Ph.D., director of KYNTRA BIO, INC., resigns the role, effective September 30, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Oct 1, 2026Role: director
Last verified Nov 8, 2026